Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Allergan Revenues Rise In Q1
Allergan has posted a net income of $169m for the first quarter of 2010, compared to $45m for the prior year period. Operating income was $250.3m, compared to
Allergan has posted a net income of $169m for the first quarter of 2010, compared to $45m for the prior year period. Operating income was $250.3m, compared to
Avanir Pharmaceuticals expects the FDA to classify the response as a Class 2 resubmission, which would result in an expected review period of 180 days and potential approval
NexMed claimed that the incorporation of NexAct enabled the dose of A6 to be cut by half, or from twice per day to once per day delivered subcutaneously,
LifeCodexx aims to establish ‘Next Generation Molecular Diagnostics’ in Europe. This will provide improved diagnostics for targeted, cost-efficient treatments. The test development currently being undertaken also receives public
pSivida’s Iluvien is an injectable, non-erodable, intravitreal implant for the treatment of DME, a potentially blinding condition that affects approximately one million people in the US. Iluvien is
Watson’s ANDA is for a generic equivalent of Wyeth’s Rapamune tablets product. The suit was filed on 28 April, 2010 in the US District Court for the District
Caldolor is used primarily in hospitalised patients who are unable to receive oral therapies for pain relief and fever reduction. If approved for marketing in Canada, it would
Roche’s T-emerge Phase III clinical trials are designed as multicenter, multi-country, randomized, controlled (active or placebo), double-blind and open studies. Over 6,000 patients will be enrolled in the
Richard Clark, currently chairman, president and CEO, is expected to continue leading the company as chairman and CEO. Kenneth Frazier, currently president of the Global Human Health worldwide
The approval is based on data from the pivotal SATURN study which showed that compared to placebo Tarceva gave patients with stable disease a 39% improvement in overall